Active Ingredient: Lenograstim
Lenograstim is indicated in adults, adolescents and children aged older than 2 years for the reduction of the duration of severe neutropenia and its associated complications in patients undergoing established cytotoxic therapy associated with a significant incidence of febrile neutropenia.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
150 - 150 ug per m² of body surface area (BSA)
From 150 To 150 ug per m² of body surface area (BSA) once every day
Lenograstim should be administered daily at the recommended dose of 19.2 MIU (150 µg) per m² per day as a subcutaneous injection. The first dose should not be administered less than 24 hours following cytotoxic chemotherapy. Daily administration of lenograstim should continue until the expected nadir has passed and the neutrophil count returns to a stable level compatible with treatment discontinuation, with, if necessary, a maximum of 28 consecutive days of treatment.
A transient increase in neutrophil count may occur within the first 2 days of treatment, however lenograstim treatment should not be stopped, since the subsequent nadir usually occurs earlier and recovers more quickly if treatment continues.
Subcutaneous
19,200,000 - 19,200,000 [iU] per m² of body surface area (BSA)
From 19,200,000 To 19,200,000 [iU] per m² of body surface area (BSA) once every day
Lenograstim should be administered daily at the recommended dose of 19.2 MIU (150 µg) per m² per day as a subcutaneous injection. The first dose should not be administered less than 24 hours following cytotoxic chemotherapy. Daily administration of lenograstim should continue until the expected nadir has passed and the neutrophil count returns to a stable level compatible with treatment discontinuation, with, if necessary, a maximum of 28 consecutive days of treatment.
A transient increase in neutrophil count may occur within the first 2 days of treatment, however lenograstim treatment should not be stopped, since the subsequent nadir usually occurs earlier and recovers more quickly if treatment continues.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.